Search results :

Tazarotene

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: D05AX05

Side effects

Options: Hide MedDRA Preferred Terms

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7
Skin exfoliation Skin exfoliation 3% - 40% x x x x x x
Localized exfoliation x
Erythema Erythema 3% - 34% x x x x x x x
Burning sensation Burning sensation 1% - 26% x x x
Dry skin Dry skin 3% - 16% x x x x x x
Application site irritation Application site irritation 1.21% - 14.4% x
Pruritus Pruritus 1% - 10% x x x x x x x
Skin irritation Skin irritation 1% - 10% x
Dermatitis contact Dermatitis irritant contact 1% - 8% x x x x
Dermatitis contact x x
Application site dryness Application site dryness 1.08% - 6.72% x
Application site erythema Application site erythema 0.405% - 6.45% x
Application site exfoliation Application site exfoliation 0.405% - 5.91% x
Acne Acne 3% x x x x x
Dermatitis Rash 1% - 3% x x x x x x x
Dermatitis x x x x x x
Rash Rash 1% - 3% x x x x x x x
Pain Stinging 1% - 3% x x x x x x x
Pain x
Application site pruritus Application site pruritus 0.405% - 0.941% x
Application site pain Application site pain 0% - 1.21% x
Instillation site pain Application site pain 0% - 1.21% x
Cheilitis Cheilitis 0% - 1% x
Application site rash Application site rash 0.135% - 0.806% x
Blister Blister x
Dermatitis bullous Blister x
Eczema Eczema x x x
Oedema Oedema x x
Localised oedema Localised oedema x x
Facial pain Facial pain x x
Haemorrhage Haemorrhage x x
Haemoglobin Haemorrhage x x
Hypertriglyceridaemia Hypertriglyceridaemia x x x
Blood triglycerides increased Hypertriglyceridaemia x x x
Impetigo Impetigo x
Inflammation Inflammation x
Swelling Swelling x
Oedema peripheral Oedema peripheral x x x
Skin discolouration Skin discolouration x x
Skin hyperpigmentation Skin hyperpigmentation x x
Leukoderma Leukoderma x
Discomfort Discomfort x
Pain of skin Pain of skin x x x x x
Sensitisation Sensitisation x x x x x x
Photosensitivity reaction Phototoxicity x x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

TAZAROTENE

Side effects:17
Source:FDA Structured Product Label

tazarotene / AVAGE

Side effects:16
Source:FDA

TAZAROTENE / AVAGE

Side effects:14
Source:FDA

tazarotene

Side effects:17
Source:FDA Structured Product Label

tazarotene / Tazorac

Side effects:17
Source:FDA

TAZAROTENE

Side effects:15
Source:FDA Structured Product Label

tazarotene

Side effects:19
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label